The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With Metastatic Breast Cancer Treated With First Line Regimens Based On AvaStin
Sponsor study identifier
observational
83
1 country
1
Study Start
June 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2015
Actual (reported)Study Completion
October 2015
Actual (reported)This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. Patients will be followed for up to 12 months after progressive disease occurs.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2015
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2010
Date type not reportedThis date has not been verified as actual or estimated.
January 13, 2011
Actual (reported)January 14, 2011
Actual (reported)October 2015
Actual (reported)October 2015
Actual (reported)Correlation between the time from start of chemotherapy to the start of Avastin treatment with progression-free survival
60 months
Overall survival
60 months
Safety: Incidence of adverse events
60 months
Female patients with metastatic HER2 negative breast cancer. First-line treatment with Avastin
Cluj-Napoca, 400015, Romania
Clinical Trials
Hoffmann-La Roche
83 participants (actual enrollment reported by the registry).
First Submitted
January 13, 2011
First Posted
January 14, 2011
Study Start
June 2010
Date type not reportedThis date has not been verified as actual or estimated.
An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer
Contact the study team to confirm eligibility.
Primary Completion
October 2015
Actual (reported)Study Completion
October 2015
Actual (reported)Last Updated
November 2, 2016
Record last verified: 2016-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: